scorecardresearch
Saturday, Dec 03, 2022
Premium

Hetero to manufacture 100 million doses of Sputnik V for India

Sputnik V is also expected to be tested in mid- to late-stage clinical trials in India by Dr Reddy's Laboratories, another Hyderabad-headquartered drugmaker.

Coronavirus vaccine, Sputnik V, Covid-19, Russian Covid vaccine, Russia coronavirus, Covid cases, MERS virus, Middle East Respiratory syndrome, Indian express opinionA view of a vial of Russia's experimental Sputnik V coronavirus vaccine. (Photo: AP)

Hyderabad-based drugmaker Hetero Drugs, through its biologics arm, will be producing “over” 100 million doses of Russian Covid-19 vaccine Sputnik V starting 2021, said the Russian Direct Investment Fund (RDIF) Friday.

The firm, through subsidiary Hetero Biopharma, is expected to produce these doses over the course of the year, according to RDIF. The vaccines produced here may also be used to fulfill demand from other countries.

Sputnik V is also expected to be tested in mid- to late-stage clinical trials in India by Dr Reddy’s Laboratories, another Hyderabad-headquartered drugmaker.

According to the latest interim analysis of data collected from participants undergoing Sputnik V trials in Russia, the vaccine seems to have demonstrated an efficacy of 91.4%.

Subscriber Only Stories
UPSC Essentials| Weekly news express with MCQs : Project GIB, Remittances...Premium
Delhi Confidential: Why CJI Chandrachud says children should be taught as...Premium
Shaped by war: Ukraine artist to showcase work at Kochi-Muziris BiennalePremium
Most drones crossing border originate from Pak Rangers outposts: AgenciesPremium

Also Read | Sputnik V maker says vaccine to be priced under $20 per person

“Requests for more than 1.2 billion doses of Sputnik V vaccine came from more than 50 countries. The vaccine supplies for the global market will be produced by RDIF’s international partners in India, Brazil, China, South Korea and other countries,” stated RDIF in a release.

“While we look forward to the clinical trial results in India, we believe that manufacturing the product locally is crucial to enable swift access to patients,” said B Murali Krishna Reddy, Director – International Marketing, Hetero Labs Limited.

Advertisement

Explained | 5 reasons Oxford-AstraZeneca vaccine is better news than Pfizer, Moderna shots

“Thanks to our cooperation with Hetero, we will be able to significantly increase production capacity and provide people of India with an efficient solution in this challenging period of the pandemic,” said Kirill Dmitriev, CEO of the Russian sovereign wealth fund.

First published on: 27-11-2020 at 12:09:04 pm
Next Story

US, Taiwan to push an alternative to China’s Belt and Road

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
Advertisement
close